NEW YORK, Oct. 14, 2019 — Hoth Therapeutics, Inc.(NASDAQ: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound […]
Hoth Therapeutics, Inc. (NASDAQ: HOTH) Next Super Stock investor conference presentation 9/26/2019 Hoth Therapeutics (NASDAQ: HOTH) is targeting multi-billion dollar market opportunities, with it’s pipeline of targeted dermatological therapies for eczema, psoriasis, chronic wound disorders, […]
VANCOUVER, Washington, Oct. 01, 2019– CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today FDA clearance […]
VANCOUVER, Washington, Sept. 09, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that […]
VANCOUVER, Washington, Sep 06, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that […]
NEW YORK, Sept. 6, 2019 — Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, […]
Hoth Therapeutics, Inc. (NASDAQ: HOTH) will be a featured presenter at Wall Street Reporter’s Next Super Stock Live! online investor conference on September 25, 2019. Hoth Therapeutics, Inc. (NASDAQ: HOTH) Interview […]
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis to chronic wound disorders, today issued a letter to shareholders. Dear Shareholder, I […]
VANCOUVER, Washington, Aug. 29, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that […]
Greenville, SC, Aug. 22, 2019 — Zylo Therapeutics, dedicated to bringing innovative topical technologies to multiple facets of medicine, has entered into a definitive partnership agreement with Hoth Therapeutics (NASDAQ: HOTH) to develop a new treatment for […]
CytoDyn, Inc. (OTC: CYDY) Next Super Stock investor conference presentation 8/15/2019
VANCOUVER, Washington, Aug. 08, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the […]
VANCOUVER, Washington, Aug. 06, 2019 – CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the […]
Agreement represents a revenue opportunity as a diagnostic test for receptor occupancy and the existence of CCR5 on cancer tissue and in HIV VANCOUVER, Washington, Jul 26, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the […]
VANCOUVER, Washington, Jul 25, 2019– – FDA face-to-face meeting granted to discuss pivotal monotherapy trial – Conference call for investors and media on Tuesday, July 30, 2019 at 4:00 p.m. ET with introduction to Dr. […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
